Market research
7R9B.F Qualigen Therapeutics, Inc
F EUR Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
Market facts
- Market cap
- 7M
- P/E ratio
- Not available
- Analyst target
- 7.75
- Dividend yield
- 0.0%
- Beta
- 0.06
Profile
Company facts
- Exchange
- F
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- Not available
- Market cap
- 7M
- P/E ratio
- Not available
- Analyst target
- 7.75
- Dividend yield
- 0.0%
- Beta
- 0.06
About
About Qualigen Therapeutics, Inc
Qualigen Therapeutics, Inc., a biotechnology company, develops novel therapeutic products for the treatment of cancer and infectious diseases. It offers FastPack, a rapid diagnostic testing system. The company is developing QN-302 for the treatment of pancreatic ductal adenocarcinoma; QN-247, a DNA coated gold nanoparticle cancer drug candidate that targets various cancers; RAS-F, a small-molecule RAS oncogene protein-protein inhibitor that blocks RAS mutations and inhibits tumor formation; and STARS blood cleansing system, a DNA/RNA-based treatment device that removes tumor-produced compounds and viruses from a patient's blood. Qualigen Therapeutics, Inc. was founded in 1996 and is based in Carlsbad, California.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the 7R9B.F discussion.
5 years, 5 months ago
Qualigen Therapeutics, Inc is currently in a long term downtrend where the price is trading 36.9% below its 200 day moving average.
From a valuation standpoint, the stock is 99.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 12.6.
Finally, its free cash flow fell by 1255.1% to $-5M since the same quarter in the previous year.
Based on the above factors, Qualigen Therapeutics, Inc gets an overall score of 1/5.